AU2021311597B2 - Compositions and methods for activating pyruvate kinase - Google Patents
Compositions and methods for activating pyruvate kinaseInfo
- Publication number
- AU2021311597B2 AU2021311597B2 AU2021311597A AU2021311597A AU2021311597B2 AU 2021311597 B2 AU2021311597 B2 AU 2021311597B2 AU 2021311597 A AU2021311597 A AU 2021311597A AU 2021311597 A AU2021311597 A AU 2021311597A AU 2021311597 B2 AU2021311597 B2 AU 2021311597B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- methyl
- dihydro
- pyridazino
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054478P | 2020-07-21 | 2020-07-21 | |
| US63/054,478 | 2020-07-21 | ||
| PCT/US2021/042489 WO2022020424A1 (en) | 2020-07-21 | 2021-07-21 | Compositions and methods for activating pyruvate kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021311597A1 AU2021311597A1 (en) | 2023-02-02 |
| AU2021311597B2 true AU2021311597B2 (en) | 2026-08-06 |
Family
ID=79728915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021311597A Active AU2021311597B2 (en) | 2020-07-21 | 2021-07-21 | Compositions and methods for activating pyruvate kinase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230374017A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185293A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023535027A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249531A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021311597B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183980A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020424A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233063B2 (en) | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
| WO2023052783A1 (en) * | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| CN118434720A (zh) | 2021-12-22 | 2024-08-02 | 西特瑞治疗有限公司 | 作为丙酮酸激酶调节剂的酞嗪衍生物 |
| WO2023211999A1 (en) * | 2022-04-29 | 2023-11-02 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137320A1 (en) * | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
| WO2019035865A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals Inc. | MODULATORS OF PYRUVATE KINASE AND THEIR USE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563580B2 (en) * | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2968323A4 (en) * | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| US12233063B2 (en) * | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
| US20220127267A1 (en) * | 2019-02-13 | 2022-04-28 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
-
2021
- 2021-07-21 CA CA3183980A patent/CA3183980A1/en active Pending
- 2021-07-21 US US18/017,108 patent/US20230374017A1/en active Pending
- 2021-07-21 AU AU2021311597A patent/AU2021311597B2/en active Active
- 2021-07-21 JP JP2023504298A patent/JP2023535027A/ja active Pending
- 2021-07-21 CN CN202180058558.3A patent/CN116249531A/zh active Pending
- 2021-07-21 WO PCT/US2021/042489 patent/WO2022020424A1/en not_active Ceased
- 2021-07-21 EP EP21846999.7A patent/EP4185293A4/en active Pending
-
2026
- 2026-02-10 JP JP2026020484A patent/JP2026097841A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137320A1 (en) * | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
| WO2019035865A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals Inc. | MODULATORS OF PYRUVATE KINASE AND THEIR USE |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183980A1 (en) | 2022-01-27 |
| JP2023535027A (ja) | 2023-08-15 |
| EP4185293A1 (en) | 2023-05-31 |
| US20230374017A1 (en) | 2023-11-23 |
| EP4185293A4 (en) | 2025-01-15 |
| JP2026097841A (ja) | 2026-06-16 |
| WO2022020424A1 (en) | 2022-01-27 |
| CN116249531A (zh) | 2023-06-09 |
| AU2021311597A1 (en) | 2023-02-02 |